Swiss drug maker gears up to launch first in class Tekturna.
Novartis is hoping to make a big splash with its newest hypertension drug, shaking up a sluggish market that has seen little innovation over the past decade. Tekturna (aliskiren), which boasts a novel mechanism of action, is one of two major launches coming out of the company's cardiovascular franchise this year. Debut number two is Exforge--which combines its best seller, Diovan (valsartan), with the generic version of Pfizer's Norvasc (amlodipine)--with a multifaceted third-quarter blitz including community outreach, disease awareness, and a celebrity spokesperson.
The Swiss giant is also pulling out all the stops for Tekturna. "Everyone should expect we'll have a competitive launch," said Mark Iwicki, vice president of the cardiovascular brand team. Without giving too much away, he noted that Novartis is contacting 85,000 physicians and preparing a comprehensive med-ed program. The company has added 1,000 sales reps in the US to support new-product launches, including Exforge and Tekturna, according to the company's annual report.
Tekturna is the first in a class of drugs called direct renin inhibitors, which have been 30 years in the making. While other drugs try to control the effects of renin, Tekturna blocks its production from the get-go. "It's been a hard mechanism to master and bring to market," Iwicki said. The promise, however, is a drug that could have better efficacy than those already available.
Yet Novartis will be introducing its newcomer into a field that is crowded with good generics. And it will also need to guard against the ever-present frustration of patient noncompliance, especially tricky for a silent killer like hypertension.
The firm is currently funding a number of "outcome" mega-studies that could one day allow it to market the drug for additional indications. In the meantime, it expects Diovan to remain its first-line therapy for hypertension, with Tekturna prescribed when patients need additional therapy--as most do. "This product can absolutely be used first line, [but] managed-care plans are really pushing generics right now," Iwicki said about Tekturna. "A large piece of the business will be in combination with other drugs."
Diovan, one of four hypertension drugs in Novartis' portfolio, grew 15 percent last year to $4.2 billion.
On the consumer front, patients who take Tekturna will be able to sign up for the company's BP Success Zone, a program that uses a number of tools to drive home the message of why it's important to stick to therapy. Doctors also get help--like 3-D images of the havoc high blood pressure wreaks inside the body--communicating the point.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.